Search

Your search keyword '"Clemens, Ralf"' showing total 422 results
Start Over Author "Clemens, Ralf"
422 results on '"Clemens, Ralf"'

2. Indirect effectiveness of a novel SARS-COV-2 vaccine (SCB-2019) in unvaccinated household contacts in the Philippines: A cluster randomised analysis

Author

Aziz, Asma Binte, Sugimoto, Jonathan Dewing, Hong, Sye Lim, You, Young Ae, Bravo, Lulu, Roa, Camilo, Jr, Borja-Tabora, Charissa, Montellano, May Emmeline B., Carlos, Josefina, de Los Reyes, Mari Rose A., Alberto, Edison R., Salvani-Bautista, Milagros, Kim, Hwa Young, Njau, Irene, Clemens, Ralf, Marks, Florian, and Tadesse, Birkneh Tilahun

Published
2024
Full Text
View/download PDF

4. The faces behind vaccination: unpacking the attitudes, knowledge, and practices of staff of Cameroon’s Expanded program on Immunization

Author

Saidu, Yauba, Gu, Jessica, Ngenge, Budzi Michael, Nchinjoh, Sangwe Clovis, Adidja, Amani, Nnang, Nadege Edwidge, Muteh, Nkwain Jude, Zambou, Vouking Marius, Mbanga, Clarence Mvalo, Agbor, Valirie Ndip, Ousmane, Diaby, Njoh, Andreas Ateke, Flegere, Junie, Diack, Demba, Wiwa, Owens, Montomoli, Emanuele, Clemens, Sue Ann Costa, and Clemens, Ralf

Published
2023
Full Text
View/download PDF

5. Assessment of immunization data management practices in Cameroon: unveiling potential barriers to immunization data quality

Author

Saidu, Yauba, Gu, Jessica, Ngenge, Budzi Michael, Nchinjoh, Sangwe Clovis, Adidja, Amani, Nnang, Nadege Edwidge, Muteh, Nkwain Jude, Zambou, Vouking Marius, Mbanga, Clarence, Agbor, Valirie Ndip, Ousmane, Diaby, Njoh, Andreas Ateke, Flegere, Junie, Diack, Demba, Wiwa, Owens, Montomoli, Emmanuele, Clemens, Sue Ann Costa, and Clemens, Ralf

Published
2023
Full Text
View/download PDF

7. Immunogenicity of an adjuvanted SARS-CoV-2 trimeric S-protein subunit vaccine (SCB-2019) in SARS-CoV-2-naïve and exposed individuals in a phase 2/3, double-blind, randomized study

Author

Buntinx, Erik, Brochado, Leonardo, Borja-Tabora, Charissa, Yu, Charles Y., Alberto, Edison R, Montellano, May Emmeline B., Carlos, Josefina C., Toloza, Leonardo Bautista, Hites, Maya, Siber, George, Clemens, Ralf, Ambrosino, Donna, Qin, Haijing, Chen, Hui Ling, Han, Htay Htay, Hu, Branda, Li, Ping, Baccarini, Carmen, and Smolenov, Igor

Published
2023
Full Text
View/download PDF

8. Evaluation of the safety, immunogenicity, and faecal shedding of novel oral polio vaccine type 2 in healthy newborn infants in Bangladesh: a randomised, controlled, phase 2 clinical trial

Author

Zaman, Khaelqu, Bandyopadhyay, Ananda S, Hoque, Masuma, Gast, Christopher, Yunus, Mohammad, Jamil, Khondoker M, Mainou, Bernardo A, Konopka-Anstadt, Jennifer L, Hendley, William S, Vincent, Annelet, Clemens, Ralf, Clemens, Sue Ann Costa, Ross, Allen G, Clemens, John D, and Tritama, Erman

Published
2023
Full Text
View/download PDF

14. The safety and immunogenicity of two novel live attenuated monovalent (serotype 2) oral poliovirus vaccines in healthy adults: a double-blind, single-centre phase 1 study

Author

Van Damme, Pierre, De Coster, Ilse, Bandyopadhyay, Ananda S, Revets, Hilde, Withanage, Kanchanamala, De Smedt, Philippe, Suykens, Leen, Oberste, M Steven, Weldon, William C, Costa-Clemens, Sue Ann, Clemens, Ralf, Modlin, John, Weiner, Amy J, Macadam, Andrew J, Andino, Raul, Kew, Olen M, Konopka-Anstadt, Jennifer L, Burns, Cara C, Konz, John, Wahid, Rahnuma, and Gast, Christopher

Subjects
Clinical Research, Biotechnology, Infectious Diseases, Clinical Trials and Supportive Activities, Rare Diseases, Prevention, Immunization, Vaccine Related, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, 3.4 Vaccines, Prevention of disease and conditions, and promotion of well-being, Infection, Good Health and Well Being, Adult, Antibodies, Viral, Double-Blind Method, Feces, Female, Humans, Immunogenicity, Vaccine, Male, Middle Aged, Poliomyelitis, Poliovirus, Poliovirus Vaccine, Oral, RNA, Viral, Single-Blind Method, Vaccines, Attenuated, Virulence, Virus Shedding, Young Adult, Medical and Health Sciences, General & Internal Medicine
Abstract

BackgroundUse of oral live-attenuated polio vaccines (OPV), and injected inactivated polio vaccines (IPV) has almost achieved global eradication of wild polio viruses. To address the goals of achieving and maintaining global eradication and minimising the risk of outbreaks of vaccine-derived polioviruses, we tested novel monovalent oral type-2 poliovirus (OPV2) vaccine candidates that are genetically more stable than existing OPVs, with a lower risk of reversion to neurovirulence. Our study represents the first in-human testing of these two novel OPV2 candidates. We aimed to evaluate the safety and immunogenicity of these vaccines, the presence and extent of faecal shedding, and the neurovirulence of shed virus.MethodsIn this double-blind, single-centre phase 1 trial, we isolated participants in a purpose-built containment facility at the University of Antwerp Hospital (Antwerp, Belgium), to minimise the risk of environmental release of the novel OPV2 candidates. Participants, who were recruited by local advertising, were adults (aged 18-50 years) in good health who had previously been vaccinated with IPV, and who would not have any contact with immunosuppressed or unvaccinated people for the duration of faecal shedding at the end of the study. The first participant randomly chose an envelope containing the name of a vaccine candidate, and this determined their allocation; the next 14 participants to be enrolled in the study were sequentially allocated to this group and received the same vaccine. The subsequent 15 participants enrolled after this group were allocated to receive the other vaccine. Participants and the study staff were masked to vaccine groups until the end of the study period. Participants each received a single dose of one vaccine candidate (candidate 1, S2/cre5/S15domV/rec1/hifi3; or candidate 2, S2/S15domV/CpG40), and they were monitored for adverse events, immune responses, and faecal shedding of the vaccine virus for 28 days. Shed virus isolates were tested for the genetic stability of attenuation. The primary outcomes were the incidence and type of serious and severe adverse events, the proportion of participants showing viral shedding in their stools, the time to cessation of viral shedding, the cell culture infective dose of shed virus in virus-positive stools, and a combined index of the prevalence, duration, and quantity of viral shedding in all participants. This study is registered with EudraCT, number 2017-000908-21 and ClinicalTrials.gov, number NCT03430349.FindingsBetween May 22 and Aug 22, 2017, 48 volunteers were screened, of whom 15 (31%) volunteers were excluded for reasons relating to the inclusion or exclusion criteria, three (6%) volunteers were not treated because of restrictions to the number of participants in each group, and 30 (63%) volunteers were sequentially allocated to groups (15 participants per group). Both novel OPV2 candidates were immunogenic and increased the median blood titre of serum neutralising antibodies; all participants were seroprotected after vaccination. Both candidates had acceptable tolerability, and no serious adverse events occurred during the study. However, severe events were reported in six (40%) participants receiving candidate 1 (eight events) and nine (60%) participants receiving candidate 2 (12 events); most of these events were increased blood creatinine phosphokinase but were not accompanied by clinical signs or symptoms. Vaccine virus was detected in the stools of 15 (100%) participants receiving vaccine candidate 1 and 13 (87%) participants receiving vaccine candidate 2. Vaccine poliovirus shedding stopped at a median of 23 days (IQR 15-36) after candidate 1 administration and 12 days (1-23) after candidate 2 administration. Total shedding, described by the estimated median shedding index (50% cell culture infective dose/g), was observed to be greater with candidate 1 than candidate 2 across all participants (2·8 [95% CI 1·8-3·5] vs 1·0 [0·7-1·6]). Reversion to neurovirulence, assessed as paralysis of transgenic mice, was low in isolates from those vaccinated with both candidates, and sequencing of shed virus indicated that there was no loss of attenuation in domain V of the 5'-untranslated region, the primary site of reversion in Sabin OPV.InterpretationWe found that the novel OPV2 candidates were safe and immunogenic in IPV-immunised adults, and our data support the further development of these vaccines to potentially be used for maintaining global eradication of neurovirulent type-2 polioviruses.FundingBill & Melinda Gates Foundation.

Published
2019

16. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study

Author

Bittaye, Mustapha, Woods, Danielle, Davies, Sophie, Smith, Holly, Ulaszewska, Marta, Sanders, Helen, Mabette, Reece, Vernon, Sophie, Valliji, Zara, Mead, Gracie, Tejpal, Chitra, Park, Juyeon, Beveridge, Amy, Eldawi, Ahmed, Felle, Sally, Fraga, Mayara, Muniz Martins, Thaiane, Martins Medrado, Claudia Loureiro, de Arruda Cordeiro Matos, Laiana Januse, Costa Clemens, Sue Ann, Weckx, Lily, Clemens, Ralf, Almeida Mendes, Ana Verena, Ramos Souza, Alessandra, Silveira, Mariana B V, da Guarda, Suzete Nascimento Farias, de Nobrega, Maristela Miyamoto, de Moraes Pinto, Maria Isabel, Gonzalez, Isabela G S, Salvador, Natalia, Franco, Marilia Miranda, de Avila Mendonça, Renata Navis, Queiroz Oliveira, Isabelle Silva, de Freitas Souza, Bruno Solano, Aley, Parvinder, Bibi, Sagida, Cantrell, Liberty, Dejnirattisai, Wanwisa, Liu, Xinxue, Mongkolsapaya, Juthathip, Supasa, Piyada, Screaton, Gavin R, Lambe, Teresa, Voysey, Merryn, and Pollard, Andrew J

Published
2022
Full Text
View/download PDF

17. Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial

Author

Bravo, Lulu, Smolenov, Igor, Han, Htay Htay, Li, Ping, Hosain, Romana, Rockhold, Frank, Clemens, Sue Ann Costa, Roa, Camilo, Jr, Borja-Tabora, Charissa, Quinsaat, Antoinette, Lopez, Pio, López-Medina, Eduardo, Brochado, Leonardo, Hernández, Eder A, Reynales, Humberto, Medina, Tatiana, Velasquez, Hector, Toloza, Leonardo Bautista, Rodriguez, Edith Johana, de Salazar, Dora Ines Molina, Rodríguez, Camilo A, Sprinz, Eduardo, Cerbino-Neto, José, Luz, Kleber Giovanni, Schwarzbold, Alexandre Vargas, Paiva, Maria Sanali, Carlos, Josefina, Montellano, May Emmeline B, de Los Reyes, Mari Rose A, Yu, Charles Y, Alberto, Edison R, Panaligan, Mario M, Salvani-Bautista, Milagros, Buntinx, Erik, Hites, Maya, Martinot, Jean-Benoit, Bhorat, Qasim E, Badat, Aysha, Baccarini, Carmen, Hu, Branda, Jurgens, Jaco, Engelbrecht, Jan, Ambrosino, Donna, Richmond, Peter, Siber, George, Liang, Joshua, and Clemens, Ralf

Published
2022
Full Text
View/download PDF

18. The landscape of paediatric infectious disease exposure in a rural sub-Saharan Africa setting in Kilifi, Kenya: longitudinal serological analysis over two decades and priorities for future vaccine development

Author

Foley, Deirdre F, primary, Chege, Timothy K, additional, Kabagenyi, Joyce, additional, McCarthy, Karen, additional, Gicheru, Elijah T, additional, Kibinge, Nelson, additional, Maina, Angela W, additional, Waeni, Jacqueline M, additional, Clemens, Ralf, additional, Clemens, Sue-Ann Costa, additional, Tuju, James, additional, and Sande, Charles J, additional

Published
2024
Full Text
View/download PDF

19. Boosting with adjuvanted SCB-2019 elicits superior Fcγ-receptor engagement driven by IgG3 to SARS-CoV-2 spike

Author

Jung, Wonyeong, primary, Yuan, Dansu, additional, Kellman, Benjamin, additional, Gonzalez, Isabela Garrido da Silva, additional, Clemens, Ralf, additional, Milan, Eveline Pipolo, additional, Sprinz, Eduardo, additional, Cerbino Neto, José, additional, Smolenov, Igor, additional, Alter, Galit, additional, McNamara, Ryan P., additional, and Costa Clemens, Sue Ann, additional

Published
2024
Full Text
View/download PDF

21. Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in healthy adults: two clinical trials

Author

De Coster, Ilse, Leroux-Roels, Isabel, Bandyopadhyay, Ananda S, Gast, Christopher, Withanage, Kanchanamala, Steenackers, Katie, De Smedt, Philippe, Aerssens, Annelies, Leroux-Roels, Geert, Oberste, M Steven, Konopka-Anstadt, Jennifer L, Weldon, William C, Fix, Alan, Konz, John, Wahid, Rahnuma, Modlin, John, Clemens, Ralf, Costa Clemens, Sue Ann, Bachtiar, Novilia S, and Van Damme, Pierre

Published
2021
Full Text
View/download PDF

22. Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in children and infants: two clinical trials

Author

Sáez-Llorens, Xavier, Bandyopadhyay, Ananda S, Gast, Christopher, Leon, Tirza De, DeAntonio, Rodrigo, Jimeno, Jose, Caballero, Maria Isabel, Aguirre, Gabriela, Oberste, M Steven, Weldon, William C, Konopka-Anstadt, Jennifer L, Modlin, John, Bachtiar, Novilia S, Fix, Alan, Konz, John, Clemens, Ralf, Costa Clemens, Sue Ann, and Rüttimann, Ricardo

Published
2021
Full Text
View/download PDF

23. Novel Oral Polio Vaccine Type 2 Use for Polio Outbreak Response: A Global Effort for a Global Health Emergency.

Author

Kurji, Feyrouz Damji, Bandyopadhyay, Ananda Sankar, Zipursky, Simona, Cooper, Laura V., Gast, Chris, Toher, Margaret, Clemens, Ralf, Clemens, Sue Ann Costa, Prasad, Rayasam, and Azhari, Adriansjah

Subjects
POLIO, POLIOMYELITIS vaccines, ORAL vaccines, WORLD health, DNA vaccines, POLIOVIRUS
Abstract

A sharp rise in circulating vaccine-derived poliovirus type 2 (cVDPV2) outbreaks in the years following the cessation of routine use of poliovirus type 2-containing oral polio vaccine and the trend of seeding new emergences with suboptimal vaccination response during the same time-period led to the accelerated development of the novel oral polio vaccine type 2 (nOPV2), a vaccine with enhanced genetic stability and lower likelihood of reversion to neuroparalytic variants compared to its Sabin counterpart. In November 2020, nOPV2 became the first vaccine to be granted an Emergency Use Listing (EUL) by the World Health Organization (WHO) Prequalification Team (PQT), allowing close to a billion doses to be used by countries within three years after its first rollout and leading to full licensure and WHO prequalification (PQ) in December 2023. The nOPV2 development process exemplifies how scientific advances and innovative tools can be applied to combat global health emergencies in an urgent and adaptive way, building on a collaborative effort among scientific, regulatory and implementation partners and policymakers across the globe. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

24. Development of a composite scoring system to rank communities at high risk of zero-dose children in Cameroon: A geospatial analysis

Author

Saidu, Yauba, primary, Agbor, Valirie N, additional, Di Mattei, Pietro, additional, Nchinjoh, Sangwe C, additional, Edwidge, Nnang N, additional, Njoh, Andreas A, additional, Muteh, Nkwain J, additional, Prescott, Marta, additional, Wiwa, Owens, additional, Diack, Demba, additional, Flegere, Junie, additional, Montomoli, Emanuele, additional, Costa Clemens, Sue A, additional, and Clemens, Ralf, additional

Published
2023
Full Text
View/download PDF

29. Superior Boosting of Neutralizing Titers Against Omicron SARS-CoV-2 Variants by Heterologous SCB-2019 Vaccine vs a Homologous Booster in CoronaVac-Primed Adults

Author

Roa, Camilo C, primary, de Los Reyes, Mari Rose A, additional, Plennevaux, Eric, additional, Smolenov, Igor, additional, Hu, Branda, additional, Gao, Faith, additional, Ilagan, Hannalyn, additional, Ambrosino, Donna, additional, Siber, George, additional, and Clemens, Ralf, additional

Published
2023
Full Text
View/download PDF

32. Utilizing Reconfigurable Hardware Processors via Grid Services

Author

Nathan, Darran and Clemens, Ralf

Subjects
Computer Science - Distributed, Parallel, and Cluster Computing, Computer Science - Hardware Architecture
Abstract

Computational grids typically consist of nodes utilizing ordinary processors such as the Intel Pentium. Field Programmable Gate Arrays (FPGAs) are able to perform certain compute-intensive tasks very well due to their inherent parallel architecture, often resulting in orders of magnitude speedups. This paper explores how FPGAs can be transparently exposed for remote use via grid services, by integrating the Proteus Software Platform with the Globus Toolkit 3.0., Comment: 3 pages, 8 figures

Published
2004

34. The Immunogenicity of Fractional Intradermal Doses of the Inactivated Poliovirus Vaccine Is Associated With the Size of the Intradermal Fluid Bleb

Author

Bibby, Jack, Saidu, Yauba, Umesi, Ama, Moneke-Anyanwoke, Ngozi, Bashorun, Adedapo O., Hydara, Mariama Badjie, Adigweme, Ikechukwu, Adetifa, Jane U., Okoye, Michael, Roberts, Elishia, Clemens, Ralf, Bandyopadhyay, Ananda S., Muhammad, Abdul K., Mulwa, Sarah, Royals, Michael, Jarrahian, Courtney, Jeffries, David, Kampmann, Beate, and Clarke, Ed

Published
2017

35. Assessment of immunization data management practices in Cameroon: Unveiling potential barriers to immunization data quality

Author

Saidu, Yauba, primary, Gu, Jessica, additional, Ngenge, Budzi Michael, additional, Nchinjoh, Sangwe Clovis, additional, Adidja, Amani, additional, Nnang, Nadege Edwige, additional, Muteh, Nkwain Jude, additional, Zambou, Vouking Marius, additional, Mbanga, Clarence Mvalo, additional, Agbor, Valirie Ndip, additional, Ousmane, Diaby, additional, Njoh, Andreas Ateke, additional, Flegere, Junie, additional, Diack, Demba, additional, Wiwa, Owens, additional, Montomoli, Emmanuele, additional, Clemens, Sue Costa, additional, and Clemens, Ralf, additional

Published
2023
Full Text
View/download PDF

40. Pertussis Antibodies and Vaccination Coverage Among Healthcare Professionals in Brazil is Inadequate: A Cross-Sectional Serological Study

Author

Cardona, Rita Soares Barbosa, primary, Weckx, Lily Yin, additional, de Moraes Pinto, Maria Isabel, additional, Ramos, Bárbara Cristina Ferreira, additional, dos Santos, Andréia Regina Augusto, additional, Spina, Fernanda Garcia, additional, de Araújo, Beatriz Collaço, additional, Costa, Sue Ann, additional, and Clemens, Ralf, additional

Published
2023
Full Text
View/download PDF

41. Safety and immunogenicity of inactivated poliovirus vaccine when given with measles–rubella combined vaccine and yellow fever vaccine and when given via different administration routes: a phase 4, randomised, non-inferiority trial in The Gambia

Author

Clarke, Ed, Saidu, Yauba, Adetifa, Jane U, Adigweme, Ikechukwu, Hydara, Mariama Badjie, Bashorun, Adedapo O, Moneke-Anyanwoke, Ngozi, Umesi, Ama, Roberts, Elishia, Cham, Pa Modou, Okoye, Michael E, Brown, Kevin E, Niedrig, Matthias, Chowdhury, Panchali Roy, Clemens, Ralf, Bandyopadhyay, Ananda S, Mueller, Jenny, Jeffries, David J, and Kampmann, Beate

Published
2016
Full Text
View/download PDF

42. Humoral and intestinal immunity induced by new schedules of bivalent oral poliovirus vaccine and one or two doses of inactivated poliovirus vaccine in Latin American infants: an open-label randomised controlled trial

Author

Asturias, Edwin J, Bandyopadhyay, Ananda S, Self, Steve, Rivera, Luis, Saez-Llorens, Xavier, Lopez, Eduardo, Melgar, Mario, Gaensbauer, James T, Weldon, William C, Oberste, M Steven, Borate, Bhavesh R, Gast, Chris, Clemens, Ralf, Orenstein, Walter, O'Ryan G, Miguel, Jimeno, José, Clemens, Sue Ann Costa, Ward, Joel, and Rüttimann, Ricardo

Published
2016
Full Text
View/download PDF

43. Immunogenicity, safety and reactogenicity of heterologous (third dose) booster vaccination with a full or fractional dose of two different COVID-19 vaccines: A phase 4, single-blind, randomized controlled trial in adults

Author

Clemens, Sue Ann Costa, Marchevsky, Natalie, Kelly, Sarah, Felle, Sally, Eldawi, Ahmed, Rajasingam, Rupetha, Mahmud, Rawan, Lambe, Teresa, Voysey, Merryn, Gonzalez, Isabela, Milan, Eveline Pipolo, Justino, Maria Cleonice, Bibi, Sagida, Aley, Parvinder, Clemens, Ralf, and Pollard, Andrew J.

Abstract

In this phase 4 study we assessed boosting with fractional doses of heterologous COVID-19 vaccines in Brazilian adults primed with two doses of CoronaVac (Sinovac/Butantan, São Paulo, Brazil) at least 4 months previously. Participants received either full-dose of ChAdOx1-S (Group 1, n = 232), a half dose of ChAdOx1-S (Group 2, n = 236), or a half dose of BNT162b2 (Group 3, n = 234). The primary objective was to show 80% seroresponse rates (SRR) 28 d after vaccination measured as IgG antibodies against a prototype SARS-CoV-2 spike-protein. Safety was assessed as solicited and unsolicited adverse events. At baseline all participants were seropositive, with high IgG titers overall. SRR at Day 28 were 34.3%, 27.1% and 71.2%, respectively, not meeting the primary objective of 80%, despite robust immune responses in all three groups with geometric mean-fold rise (GMFR) in IgG titers of 3.39, 2.99 and 7.42, respectively. IgG immune responses with similar GMFR were also observed against SARS-CoV-2 variants, Alpha, Beta, Delta, Gamma and D614G. In subsets (n = 35) of participants GMFR of neutralizing immune responses against live prototype SARS-CoV-2 virus and Omicron BA.2 were similar to the IgG responses as were pseudo-neutralizing responses against SARS-CoV-2 prototype and Omicron BA.4/5 variants. All vaccinations were well tolerated with no vaccine-related serious adverse events and mainly transient mild-to-moderate local and systemic reactogenicity. Heterologous boosting with full or half doses of ChAdOx1-S or a half dose of BNT162b2 was safe and immunogenic in CoronaVac-primed adults, but seroresponse rates were limited by high baseline immunity.

Published
2023
Full Text
View/download PDF

44. Heterologous boosting of neutralizing activity against Delta and Omicron SARS-CoV-2 variants in CoronaVac-primed adults; a randomized study with SCB-2019 vaccine

Author

Roa, Camilo C., primary, de Los Reyes, Mari Rose A., additional, Plennevaux, Eric, additional, Smolenov, Igor, additional, Hu, Branda, additional, Gao, Faith, additional, Ilagan, Hannalyn, additional, Ambrosino, Donna, additional, Siber, George, additional, and Clemens, Ralf, additional

Published
2022
Full Text
View/download PDF

46. Safety of the Fiocruz ChAdOx COVID-19 vaccine used in a mass vaccination campaign in Botucatu, Brazil

Author

Clemens, Sue Ann Costa, primary, Fortaleza, Carlos Magno Castelo Branco, additional, Crowe, Madeleine, additional, Pollard, Andrew, additional, Tasca, Karen Ingrid, additional, Grotto, Rejane Maria Tommasini, additional, Martins, Marcelo Roberto, additional, Spadaro, André Gasparini, additional, Barretti, Pasqual, additional, Verstraeten, Tom, additional, and Clemens, Ralf, additional

Published
2022
Full Text
View/download PDF

47. Effectiveness of the Fiocruz recombinant ChadOx1-nCoV19 against variants of SARS-CoV-2 in the Municipality of Botucatu-SP

Author

Costa Clemens, Sue Ann, primary, Fortaleza, Carlos Magno Castelo Branco, additional, Crowe, Madeleine, additional, Tasca, Karen Ingrid, additional, Spadaro, André Gasparini, additional, Souza-Neto, Jayme Augusto, additional, Grotto, Rejane Maria Tommasini, additional, Sider, Regina, additional, Jimeno, Jose, additional, Verstraeten, Thomas, additional, and Clemens, Ralf, additional

Published
2022
Full Text
View/download PDF

50. Homologous and Heterologous Boosting of the Chadox1-S1-S COVID-19 Vaccine With the SCB-2019 Vaccine Candidate: A Randomized, Controlled, Phase 2 Study

Author

Costa Clemens, Sue Ann, primary, Milan, Eveline Pipolo, additional, Sprinz, Eduardo, additional, Neto, José Cerbino, additional, Pacciarini, Filippo, additional, Li, Ping, additional, Chen, Hui Ling, additional, Smolenov, Igor, additional, Pollard, Andrew, additional, and Clemens, Ralf, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results